Press releases

1 2 3 10

BCE Pharma, BD and Omnitech Innovations announce strategic collaboration to provide an end-to-end compounding sterile preparation solution for Canadian pharmacies

Apr 2, 2019

BCE Pharma, BD and Omnitech Innovations announce strategic collaboration to provide an end-to-end compounding sterile preparation solution for Canadian pharmacies

Canadian National Antimicrobial Prescribing Survey: A Pilot Initiative

Mar 19, 2019

The Sinai Health System-University Health Network Antimicrobial Stewardship Program, in collaboration with BD, the National Centre for Antimicrobial Stewardship, the Guidance Group, and the Public Health Agency of Canada is undertaking a pilot initiative in Canadian Hospitals to better understand how antimicrobials are prescribed in Canada.

BD Completes Molecular Portfolio For GI Infection With New Viral Panel

Dec 20, 2018

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of its BD MAX enteric viral panel, a molecular diagnostic test for the direct qualitative detection and differentiation of enteric viral pathogens that cause viral gastroenteritis.

BD Announces completion of enterprise level cybersecurity assessment from UL

Dec 11, 2018

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL.

BD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion

Nov 29, 2018

Learn how advanced analytics can help combat a critical component of the opioid epidemic at the #ASHP18 Midyear Meeting

New Diagnostic Test Helps Hospitals More Quickly Identify and Treat Emerging Antibiotic-Resistant Bacteria

Nov 13, 2018

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of the BD Phoenix CPO detect test, which will allow hospitals to identify infections caused by carbapenemase-producing organisms (CPOs).

Survey reveals Canadians largely unaware of threat of Antimicrobial Resistance

Nov 6, 2018

Mississauga, Ontario, Nov. 6, 2018 – In acknowledgement of World Antibiotic Awareness Week, Nov. 12-18, a new survey examining Canadians’ understanding of antimicrobial resistance (AMR) reveals that many are unfamiliar with and unconcerned about the threat of drug resistance.

BD MedMined Earns Meaningful Use Stage 2 Certification for Antimicrobial Use and Resistance Reporting

Oct 29, 2018

BD MedMined Earns Meaningful Use Stage 2 Certification for Antimicrobial Use and Resistance Reporting

BD launches molecular test for detecting tuberculosis and multi-drug resistant TB

Oct 16, 2018

BD MAX MDR-TB Panel Obtains CE-IVD Status in Europe

BD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis

Jul 26, 2018

BD AbSeq Assay Enables Deeper Understanding of Role Individual Cells Play in the Immune System

1 2 3 10

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.